SubsidieMeestersBuilding consensus for a new approach to breast cancer prevention in women with a BRCA1 mutation
This project aims to establish consensus for a clinical trial using progesterone receptor antagonists to prevent breast and ovarian cancer in women with BRCA1 mutations.
Projectdetails
Introduction
Women with germline mutations in the BRCA1 genes face a 40-fold increased risk of developing breast and ovarian cancer. As a result, and due to a lack of other options, many women with a BRCA1 mutation choose to undergo drastic risk-reducing surgery (removal of both breasts, ovaries, and Fallopian Tubes) when they are still very young.
Current Prevention Options
Drugs currently recommended for the prevention of breast cancer, such as tamoxifen or aromatase inhibitors, do not prevent those cancers with the poorest prognosis, such as triple-negative breast cancer. Methods to prevent breast and ovarian cancers in these women are therefore a critical unmet medical need.
Role of Progesterone
We and others have identified progesterone as one of the key drivers for triple-negative breast cancer development.
Findings
- We have shown that progesterone is consistently elevated during the luteal phase of the menstrual cycle in BRCA1 mutation carriers compared to women without such a mutation.
- Preliminary data point to progesterone receptor antagonists, such as mifepristone, as a promising class of drugs for primary prevention.
Challenges in Clinical Trials
Clinical trials of primary cancer prevention are extremely challenging due to the time gap between the start of the cancer-preventive treatment and the primary endpoints (i.e., cancer incidence and cancer death).
Limitations of Current Tools
Current tools do not predict the likelihood of future cancer development with sufficient accuracy to be used to determine the preventive efficacy of a new treatment.
Development of DNA Methylation Markers
We have developed DNA methylation markers reflecting tissue age and cell type that are increased in cancer tissue as well as in normal tissue from women with a BRCA1 mutation. These markers could be used to monitor preventive efficacy.
Future Directions
Clinical trials are now required to further investigate the use of antiprogestins for the prevention of breast and ovarian cancer.
Grant Objective
This ERC Proof of Concept grant aims to bring consensus among the scientific, patient, and regulatory/ethical communities regarding the design and conduct of an initial clinical trial.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 150.000 |
| Totale projectbegroting | € 150.000 |
Tijdlijn
| Startdatum | 1-9-2023 |
| Einddatum | 28-2-2025 |
| Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- UNIVERSITAET INNSBRUCKpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
MANUNKIND: Determinants and Dynamics of Collaborative ExploitationThis project aims to develop a game theoretic framework to analyze the psychological and strategic dynamics of collaborative exploitation, informing policies to combat modern slavery. | ERC STG | € 1.497.749 | 2022 | Details |
Elucidating the phenotypic convergence of proliferation reduction under growth-induced pressureThe UnderPressure project aims to investigate how mechanical constraints from 3D crowding affect cell proliferation and signaling in various organisms, with potential applications in reducing cancer chemoresistance. | ERC STG | € 1.498.280 | 2022 | Details |
Uncovering the mechanisms of action of an antiviral bacteriumThis project aims to uncover the mechanisms behind Wolbachia's antiviral protection in insects and develop tools for studying symbiont gene function. | ERC STG | € 1.500.000 | 2023 | Details |
The Ethics of Loneliness and SociabilityThis project aims to develop a normative theory of loneliness by analyzing ethical responsibilities of individuals and societies to prevent and alleviate loneliness, establishing a new philosophical sub-field. | ERC STG | € 1.025.860 | 2023 | Details |
MANUNKIND: Determinants and Dynamics of Collaborative Exploitation
This project aims to develop a game theoretic framework to analyze the psychological and strategic dynamics of collaborative exploitation, informing policies to combat modern slavery.
Elucidating the phenotypic convergence of proliferation reduction under growth-induced pressure
The UnderPressure project aims to investigate how mechanical constraints from 3D crowding affect cell proliferation and signaling in various organisms, with potential applications in reducing cancer chemoresistance.
Uncovering the mechanisms of action of an antiviral bacterium
This project aims to uncover the mechanisms behind Wolbachia's antiviral protection in insects and develop tools for studying symbiont gene function.
The Ethics of Loneliness and Sociability
This project aims to develop a normative theory of loneliness by analyzing ethical responsibilities of individuals and societies to prevent and alleviate loneliness, establishing a new philosophical sub-field.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Organ and mutation dependencies shaping the tumor microenvironmentThis project aims to analyze the tumor microenvironments of BRCA-driven cancers across four organs to identify common design principles for developing targeted therapies. | ERC COG | € 2.000.000 | 2022 | Details |
APOBEC Mutagenesis: a novel Achilles heel of Breast cancerThe AMBER project aims to unravel APOBEC mutagenesis in breast cancer to identify prevention and treatment strategies, potentially transforming it into a targetable vulnerability. | ERC ADG | € 2.499.990 | 2022 | Details |
Setting the optimal balance between metabolite supplementation and deprivation in cancer therapyThis project aims to combine targeted metabolite supplementation with global nutrient restriction to reprogram tumor metabolism, enhance treatment response, and improve survival in advanced triple-negative breast cancer patients. | ERC STG | € 1.499.250 | 2023 | Details |
Early detection of treatment response in breast cancerThe project aims to enhance breast cancer treatment through Hyperpolarized Magnetic Resonance imaging for early detection of non-responders, improving outcomes and reducing side effects. | EIC Transition | € 2.499.229 | 2024 | Details |
Organ and mutation dependencies shaping the tumor microenvironment
This project aims to analyze the tumor microenvironments of BRCA-driven cancers across four organs to identify common design principles for developing targeted therapies.
APOBEC Mutagenesis: a novel Achilles heel of Breast cancer
The AMBER project aims to unravel APOBEC mutagenesis in breast cancer to identify prevention and treatment strategies, potentially transforming it into a targetable vulnerability.
Setting the optimal balance between metabolite supplementation and deprivation in cancer therapy
This project aims to combine targeted metabolite supplementation with global nutrient restriction to reprogram tumor metabolism, enhance treatment response, and improve survival in advanced triple-negative breast cancer patients.
Early detection of treatment response in breast cancer
The project aims to enhance breast cancer treatment through Hyperpolarized Magnetic Resonance imaging for early detection of non-responders, improving outcomes and reducing side effects.